{"entity":{"id":"nct04893109","kind":"trial","name":"ATEMPT 2.0","aka":["ATEMPT 2.0: Adjuvant T-DM1 vs TH"],"tldr":"ATEMPT 2.0 compares a shorter course of T-DM1 followed by trastuzumab with paclitaxel and trastuzumab after breast surgery, tracking side effects and cancer recurrence.","summary":"ATEMPT 2.0 compares a shorter course of T-DM1 followed by trastuzumab with paclitaxel and trastuzumab after breast surgery, tracking side effects and cancer recurrence.\n\nInterventional study registered as NCT04893109, sponsored by Dana-Farber Cancer Institute. Registry phase: 2. Registry enrollment is 500 participants (estimated). Registry status checked October 10, 2026: recruiting. UCSF lists this study as open to eligible people; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"recruiting","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT04893109","url":"https://clinicaltrials.gov/study/NCT04893109"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT04893109"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["paclitaxel","trastuzumab","trastuzumab-emtansine"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04893109","phase":"2","setting":"HER2-positive breast cancer after surgery","sponsor":"Dana-Farber Cancer Institute","participation":[{"nct":"NCT04893109","source":"https://clinicaltrials.gov/study/NCT04893109","fetchedAt":"2026-10-10T20:54:18.305117Z","studySha256":"7b4fff4ec17919572250532775e2c24e08ccbf1a3de4573dabae34631dd6a6c6","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-19","leadSponsor":"Dana-Farber Cancer Institute","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":500,"enrolmentType":"ESTIMATED","siteCount":53,"recruitingSiteCount":46,"countries":["United States"]}],"started":"2021-06-16","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04893109/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}